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Cannabinoidshavebeenusedmedicinallyandrecreationallyforthousandsofyearsandtheireﬀectswereproposedtooccurmainly
via activation of the G-protein-coupled receptor CB1/CB2 (cannabinoid receptor 1/2). Discovery of potent synthetic analogs of
the natural cannabinoids as clinically useful drugs is the sustained aim of cannabinoid research. This demands that these new
compounds be free of the psychotropic eﬀects that connected with the recreational use of cannabinoids. In preclinical studies
cannabinoids displayed many of the characteristics of nonsteroidal anti-inﬂammatory drugs (NSAIDs) and it seems to be free of
unwanted side eﬀects. An increasing number of therapeutic actions of cannabinoid are being reported that do not appear to be
mediated by either CB1 or CB2, and recently nuclear receptor superfamily PPARs (peroxisome-proliferator-activated receptors)
have been suggested as the target of certain cannabinoids. This review summarizes the evidence for cannabinoid activation on
PPARs and possible associated remedial potentials.
Copyright © 2007 Y. Sun and A. Bennett. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The term cannabinoid describes a group of compounds,
which can potentially bind to the two recognised cannabi-
noid receptors (CB1/CB2). Many of these compounds are
structurally related to Δ9-tetrahydrocannabinol (THC) (Me-
choulam and Gaoni [1]), the major psychoactive component
concentrated in the ﬂowering head of the female plant of
Cannabis sativa (marijuana), which has been used medic-
inally and recreationally for thousands of years. THC ex-
hibits diverse pharmacological activities in vitro and in vivo.
These responses include alterations in cognition and mem-
ory,euphoria,immobility,analgesia,hypothermia,andseda-
tion (Howlett [2]). Although widely recognised as a drug of
abuse, it is now apparent that THC, like heroin, mimics the
functions of the endogenous cannabinoids, which have now
beenidentiﬁedandappeartohaverolesinsignallinginmany
diﬀerent tissues including the central nervous system (CNS),
immune system, and cardiovascular system (Mechoulam et
al. [3]). The most prominent physiological eﬀect of cannabis
and other cannabinoids is the short-term ability to induce a
state of euphoric intoxication in users. This intoxication is
accompanied by slight impairment of psychomotor and cog-
nitive function, a signiﬁcant increase in heart rate and a de-
crease in blood pressure. In addition there is evidence that
cannabinoids can alleviate spasticity, lower the heightened
intraocular pressure associated with glaucoma, control the
vomiting and nausea associated with cancer chemotherapy,
and reduce pain. The long-term eﬀects of cannabinoid expo-
sure include alternations in the levels of male and female sex-
ual hormones, possible teratogenic eﬀects, immunosuppres-
sion, and possible physical dependence on the compounds
(Cook et al. [4]).
Basedontheirorigins,cannabinoidreceptoragonistscan
be classiﬁed into three groups. The ﬁrst of these groups com-
prises the phytocannabinoids and includes THC and over 60
othercannabinoid compounds containedin Cannabissativa.
Cannabidiol(CBD)alsobelongstothisgroupandmaymod-
ulate the response to THC by decreasing anxiety and antag-
onizing other THC-eﬀects (Nadulski et al. [5]). The second
group includes the synthetic cannabinoids that act on CB re-
ceptors. These are a diverse set of compounds which include
dibenzopyran derivatives, such as HU210; some consists of
bicyclic and tricyclic analogues of THC, which lack the cen-
tral pyran ring common to the classical cannabinoid, such
as CP55940; some consist of aminoalkylindoles, which are
structurally very diﬀerent from THC, such as Win 55212-
2( P e r t w e e[ 6]; Martin et al. [7]). The third cannabinoid2 PPAR Research
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Figure 1: Chemical structures of cannabinoids. THC and cannabidiol are phytocannabinoids; HU 210, CP55940, and Win 55212-2 belong
to the synthetic cannabinoid group; anandamide, 2-AG, noladin ether, virodhamine, OEA, and PEA are classed as endocannabinoids.
group consists of arachidonic acid derivatives and con-
tains all the currently recognised endogenous cannabinoids
which are naturally occurring in vivo. Anandamide (arachi-
donylethanolamide) was the ﬁrst identiﬁed endocannabi-
noid,whichisabletoreproducethemosttypicalbehavioural
eﬀects of THC in rodents and was discovered in porcine
brain in 1992 (Devane et al. [8]). Following the discovery of
anandamide, 2-arachidonoylglycerol (2-AG), noladin ether
and virodhamine (Lambert and Fowler [9]) have been found
in the CNS. These compounds have cannabinoid receptor
binding activity, but their exact physiological roles are un-
known. Endocannabinoids have a short duration of action
since they are rapidly metabolised by the intracellular en-
zymessuchasfattyacidamidehydrolase(FAAH),monoglyc-
eride lipase (MGL), or N-palmitoylethanolamine-selective
acid amidase (NPAA). Some endogenous compounds such
as palmitoylethanolamide (PEA) and oleoylethanolamide
(OEA), which are structural analogues of anandamide, are
also metabolised by these enzymes (Jonsson et al. [10]). Al-
though they may not directly activate cannabinoid recep-
tors, they have cannabimimetic eﬀects and are regarded as
cannabinoids by many researchers. There are also other stan-
dard criteria for the classiﬁcation of cannabinoids, for ex-
ample, based on their chemical structures, cannabinoids can
be divided into classical cannabinoids, nonclassical cannabi-
noids, and endocannabinods (Figure 1).
Although many of the physiological responses to
cannabinoids, such as analgesia, attenuation of nausea, andY. Sun and A. Bennett 3
Table 1: Nature and synthetic ligands of PPARs.
PPARγ PPARα PPARβ
Nature ligands
Linoleic acid Palmitic acid Fatty acids
Arachidonic acid Linoleic acid Dihomo-γ-linolenic acid
15d-PGJ2 Stearic acid EPA
9-HODE Palmitoleic acid Arachidonic acid
13-HODE Oleic acid Eicosanoids
15-HETE Linoleic acid —
— Arachidonic acid —
—E i c o s a p e n t a e n o i c —
— 8(S)-HETE —
Synthetic ligands
TZDs WY-14643 L-165041
JTT-501 (isoxazolidinedione) Cloﬁbrate GW-501516
GW-7845 Gemﬁbrozil NSAIDs (antagonist)
CDDO Nafenopin —
BADGE (antagonist) Bezaﬁbrate —
LG-100641 (antagonist) Fenoﬁbrate —
appetite stimulation are generally thought to be due to ac-
tion at the CB1/CB2, studies in CB1,C B 2,o rC B 1/CB2 dou-
ble knockout mice have revealed non-CB1/CB2 receptor-
mediated responses to cannabinoids, both in the CNS and
p e r i p h e r y( H o w l e t te ta l .[ 11]). For example, anandamide
and Win 55212-2, but not THC, stimulated [35S]GTPγS
binding in the brains of CB1 knockout mice. This eﬀect was
not reversed by administration of CB1 and CB2 antagonists,
SR 141716A or SR 144528, respectively, strongly suggesting
the presence of novel non-CB1, non-CB2 cannabinoids re-
ceptors in the brain (Wiley and Martin [12]). Since the di-
versiﬁed structure of cannabinoids, their potential binding
targets show divergence as well. For example, anandamide
can bind vanilloid receptor (VR1) to produce membrane
currents or increase intracellular calcium (Smart and Jer-
man [13]). PEA has been suggested to bind an SR144528-
sensitive, non-CB2 receptor (“CB2-like” receptor) (Calig-
nano et al. [14]). Evidence has also arisen for the existence
of a brain G-protein-coupled receptor that can speciﬁcally
bind Win55212-2 but not other CB1/CB2 agonists (Di Marzo
et al. [15]; Breivogel et al. [16]). CBD has also been demon-
strated as a modest aﬃnity agonist of human 5-HT1α (5-
hydroxytryptamine) receptor (Russo et al. [17]).
In addition to G-protein-coupled receptors (GPCR) and
other plasma membrane receptors, another potential candi-
date for CB1/CB2-independent eﬀects of cannabinoids is the
PPAR (peroxisome-proliferator-activated receptor) family of
nuclear receptor transcription factors. The three subtypes of
PPARs (PPARα,P P A R β,a n dP P A R γ) play important roles in
regulation of lipid metabolism, hepatic peroxisomal enzyme
expression, insulin sensitivity, glucose homeostasis, and in-
ﬂammation.
The natural ligands for PPARs include fatty acids and
eicosanoid derivatives (Table 1). In general, PPARγ appar-
ently prefers polyunsaturated fatty acids such as linoleic
acid, arachidonic acid, and eicosapentaenoic acid. Although
most natural occurring ligands display micromolar aﬃnity
to PPARγ, an oxidized alkyl phospholipid hexadecylazelaoyl
phosphatidylcholine (azPC) was shown to bind and activate
the receptor at nanomolar range (Davies et al. [18]). This
ligand is by far the most potent natural PPARγ ligand and
has a similar aﬃnity as synthetic ligand rosiglitazone. Unlike
PPARγ,P P A R α has been found to be activated by both satu-
rated and unsaturated fatty acids, such as oleic acid, palmitic
acid, linoleic acid, and arachidonic acid with micromolar
aﬃnities (Gottlicher et al. [19]). Although the lipoxygenase
(LOX) metabolite 8(S)-HETE has been identiﬁed as a sub-
micromolar ligand for PPARα, its low concentration in cells
prohibits to classify it as a true natural ligand (Yu et al. [20]).
It is more plausible that PPARα responds to the changes of
whole-body free fatty acid pool (Chakravarthy et al. [21]) in-
stead of high-aﬃnity endogenous ligands. With a ligand se-
lectivity intermediated between PPARγ and PPARα, the nat-
ural ligands of PPARβ include a list of saturated and un-
saturated fatty acids, such as dihomo-γ-linolenic acid, EPA,
and arachidonic acid. A number of eicosanoids (PGA1 and
PGD2) were also identiﬁed to act on PPARβ (Forman et al.
[22]).AllofthesenaturaloccurringligandsbindPPARβwith
micromolar aﬃnities. Unlike natural ligands, the synthetic
ligandsofPPARsalwayshavehigheraﬃnity withtheirrecep-
torsandhavebeenwidelyusedinclinicaltrials(Table 1).The
most notable synthetic ligands of PPARγ are thiazolidine-
diones (TZDs) family which includes rosiglitazone, trogli-
tazone, ciglitazone, pioglitazone, and englitazone (Willson
et al. [23]). Among them, rosiglitazone was found to bind
PPARγ with a high aﬃnity (Kd ≈ 40nM), while others
are less potent ligands. TZDs have antidiabetic and insulin-
sensitizing activities and have been widely used as prescrip-
tion medicines. The ﬁbrates, such as fenoﬁbrate, cloﬁbrate,
and bezaﬁbrate, are PPARα ligands and have been used in4 PPAR Research
the treatment of hypertriglyceridemia. Through modiﬁca-
tion of atherogenic dyslipidemia, ﬁbrates have also been
shown to reduce coronary heart disease risk. Some PPARβ
selective ligands have also been identiﬁed, such as L-165041
and GW 501516, and these compounds have certain serum
lipid adjustment ability (Oliver Jr. et al. [24]).
The study of cannabinoids eﬀects on PPARs started from
the investigation of N-acyl ethanolamine OEA, a naturally
occurring lipid derivative structurally related to anandamide
which shares the anorectic property of other cannabinoids.
AlthoughOEAisa(albeitrelativelylow-aﬃnity)CBreceptor
agonistandcouldenhancetheactivityofotherendocannabi-
noids via an “entourage” eﬀect by inhibiting the metabolism
of other endocannabinoids, its regulation of feeding be-
haviour in rats appears to be due to its activation on PPARα
(Fu et al. [25]; Fu et al. [26]). In vivo, OEA regulates feeding
and body weight via a PPARα-dependent mechanism. OEA
reduces body weight gain and triacylglycerol content in the
liver and adipose tissues in subchronic treatments of diet-
induced obese mice, but not in PPARα-knockout mice. Sim-
ilarly, OEA induces lipolysis in both rats and wild-type mice
but not in PPARα-knockout mice (Guzm` an et al. [27]).
Other cannabinoids, in addition to OEA, may serve as
PPAR ligands as well. Recently, THC was found to activate
one member of the PPAR family, PPARγ, in a concentration-
dependent manner in transactivation assays in human em-
bryonic kidney (HEK-293) cells (O’Sullivan et al. [28]). It
also stimulated adipocyte diﬀerentiation in 3T3L1 cells, a
well-accepted property of PPARγ ligands. It has also been
demonstrated that THC can cause vasorelaxation through
activation of PPARγ. Ajulemic acid (AJA) is a synthetic
analog of THC which has no psychotropic activity in hu-
man or animal models but remains its analgesic and anti-
inﬂammatory activities (Zurier et al. [29]). AJA has been ap-
proved recently for a phase II clinical trial for reduction of
pain in humans. However, the biological eﬀects of AJA can-
not be altered by CB1 antagonist SR141716A and it does not
show any binding ability to CB1/CB2 (Pertwee [6]). Recently,
PPARγ was suggested as a possible candidate target site of
AJA(Liuetal.[30]).ThedatareporteddemonstratethatAJA
bindsselectivelytoPPARγ invitroandactivatethetranscrip-
tional activity of PPARγ in cells. In addition, AJA induces
3T3L1 cells diﬀerentiation into adipocytes and inhibits IL-
8p r o m o t e ra c t i v i t yi naP P A R γ-dependent manner (Liu et
al. [30]).
Polyunsaturated fatty acid amide anandamide was ini-
tially found to act as agonist of CB receptors. However,
there are many other pathways involved in anandamide
signalling. Anandamide activations on vanilloid receptor
(Smart and Jerman [13]), T-type Ca2+ and K+ Task-1 ion
channels have been demonstrated (Maingret et al. [31]).
Catalyzed by a Ca2+-dependent phospholipase D, anan-
damide is produced through hydrolysis of the phospho-
lipid precursor N-arachydonoyl-phosphatidylethanolamide
(Di Marzo et al. [32]). Over the past ten years, there has
been tremendous amount of eﬀort put forth in attempts
to characterize the mechanisms of anandamide transport
(Fowler et al. [33]). After uptake into cells via diﬀusion or
membrane transporters, anandamide can be hydrolysed by
FAAH and produce arachidonic acid and ethanolamine (Di
Marzo et al. [34]). Additionally, anandamide can be oxi-
dized by various lipoxygenases (LOX) and cyclooxygenase-
2 (COX-2), resulting in generation of ethanolamide analogs
of hydroxyeicosatetraenoic acid (HETEs) and prostaglandins
(prostamides)(Bursteinetal.[35]). Through both hydrolysis
and oxidation, anandamide brings some metabolites which
may be potential PPARs ligands. Recently, anandamide also
has been found to directly activate PPARγ (Bouaboula et al.
[36]) and PPARα (Sun et al. [37]). Anandamide can bind
PPARγ ligandbinding domaindirectlyandinducetranscrip-
tional activation of PPARγ in diﬀerent cell types. Anan-
damide can stimulate 3T3L1 adipocyte diﬀerentiation and
induce the expression of adipocyte diﬀerentiation mark-
e r ss u c ha sC - E B P α and aP2 as well as PerilipinA, Acrp30,
lipoprotein lipase,andPPARγ (Bouaboulaetal.[36]).Anan-
damide has also been shown to directly bind to the ligand
binding domain of PPARα by a CPA (cis-parinaric acid)-
based ﬂuorescence ligand binding assay and activate PPARα
transcriptional potency in the HeLa cell line (Sun et al. [37]).
It is worthy to mention that in the same systems, most en-
docannabinoids (OEA, anandamide, noladin ether, and vi-
rodhamine) show similar binding and transcription activ-
ity on PPARα with one important exception PEA, a satu-
rated analogue of OEA and anandamide. PEA was found
to activate PPARα in cultured cells and to induce the ex-
pression of PPARα. In vivo, PEA attenuates inﬂammation in
wild-type mice but not in PPARα-knockout mice (Lo et al.
[38]). However, PEA cannot displace CPA from PPARα lig-
and binding domain which suggests an indirect mechanism
(Sun et al. [37]). In addition to anandamide, 2-AG and no-
ladin ether, the nonhydrolyzable analog of 2-AG, have been
demonstrated to mediates the suppression of IL-2 through
PPARγ (Rockwell et al. [39]). The inhibition of IL-2 expres-
sionby2-AGandnoladinetherisindependentlyofCB1/CB2,
since similar suppression of IL-2 by 2-AG and noladin ether
wasobservedinsplenocytesderivedfromCB 1/CB2-nullmice
and CB1/CB2 antagonists failed to block inhibition of IL-
2 by 2-AG. 2-AG and noladin ether increased PPARγ tran-
scriptional potency in 3T3L1 cells, forced 3T3L1 adipocyte
diﬀerentiation, and induced the expression of adipocyte dif-
ferentiation marker aP2. The involvement of PPARγ was
further conﬁrmed by the fact that PPARγ-speciﬁc antago-
nist 2-chloro-5-nitro-N-(4-pyridyl)-benzamide (T0070907)
blocked 2-AG and noladin ether-mediated IL-2 suppression.
It is worthy to note that NS398, a COX-2 speciﬁc inhibitor,
blocked 2-AG and noladin ether-mediated IL-2 suppression
as well, suggesting the requirement for COX-2 metabolism
for the inhibition of IL-2 (Rockwell et al. [39]). Cannabi-
noids eﬀects on the PPARβ subtype have not been compre-
hensively studied yet, probably due to shortage of apparent
pharmacological signiﬁcance.
Cannabinoids eﬀects on PPARs involve a series of en-
zymes, proteins, and several interlaced pathways (Figure 2).
In order to directly act on nuclear transcriptional fac-
tors PPARs, exogenous cannabinoids need to pass through
plasma membrane and be transported into nucleus which
may involve certain membrane and intracellular trans-
porters. Genuine ligands of PPARs bind and change theY. Sun and A. Bennett 5
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Figure 2: A. Classical cannabinoids eﬀects on CB receptors. B. Possible pathways involved in cannabinoids eﬀects on PPARs, B-1. Some
cannabinoids act as genuine ligands of PPARs or RXRs, B-2. Enzymes involved in hydrolysing endocannabinoids may generate ligands of
PPARs, B-3. Endocannabinoids can be metabolised by COX-2 and LOX and generate ligands of PPARs; B-4. CB receptors activation leads to
the stimulation of MAPK pathway which may be reﬂected by PPARs (AA: arachidonic acid; AC: adenylate cyclase).
structure of the nuclear transcriptors and form asymmetri-
cal dimers with RXRs. This binding changes the conforma-
tion of the PPARs and induces binding to the PPRE, which
have been found in numerous PPAR-inducible genes. With
the help of certain coactivators or corepressors, genes tran-
scription is induced or suppressed. However, we still cannot
rule out that cannabinoids eﬀects could be indirect through
the binding of other cellular targets which in turn induces
PPARs activation. For example, FAAH, monoglyceride lipase
(MGL), and N-palmitoylethanolamine-selective acid ami-
dase (NPAA) are three key enzymes involved in hydrolysing
endocannabinoids (Vandevoorde and Lambert [40]). Degra-
dation of cannabinoids by these enzymes may generate novel
ligands of PPARs. When present in large quantities, sub-
stratesoftheseenzymescanalsocompetewithendocannabi-
noids which are bona ﬁde ligands of PPARs from degener-
ation. PEA has no binding ability with PPARγ and PPARα
in vitro, but it displays anti-inﬂammatory property in a
PPARα-dependent pathway in a mouse model (Lo et al.
[38]). NPAA is the PEA selective hydrolase which presum-
ablycontributestoPEAactivationonPPARαvia“entourage”
eﬀects (Ueda et al. [41]). Endocannabinoids can also be
metabolised by COX-2 and LOX and produce prostanoids
w h i c ha r ep r o v e dP P A R sa c t i v a t o r s( B u r s t e i ne ta l .[ 35]). An-
other possible PPAR-related target of cannabinoids is RXR.
It has been shown that polyunsaturated fatty acids includ-
ingarachidonicacidbindandactivateRXRα(L engqvistetal.
[42]). Thus, endocannabinoids, especially anandamide may
also activate RXRs that heterodimerize with PPARs. Even
cannabinoids eﬀects on CB1/CB2 can potentially lead to the
activation of PPARs. Ligand-binding to CB1/CB2 receptors
elicit a concentration-dependent increase in the activity of
mitogen-activated protein kinase (MAPK), which is inde-
pendent of adenylate cyclase inhibition (Rueda et al. [43]).
PPARs activation can be regulated through direct phospho-
rylation by diﬀerent members of MAPK family or by re-
ﬂecting MAPK modiﬁcation of other cellular components
that interfere with PPARs (Gelman et al. [44]). Considering
the complexity of the mechanisms, cannabinoids eﬀects on
PPARs need to be investigated attentively in certain circum-
stances.
The cannabinoids inﬂuences on PPARs consist of con-
siderable theoretical and therapeutic signiﬁcances. Although
many eﬀects of cannabinoids can be explained though their
actiononmembrane-associatedGprotein-coupledreceptors
CB1/CB2 and related downstream signalling cascades; nu-
clear receptors PPARs provide an additional mechanism for
cannabinoids regulation of gene transcription which may as-
sociate with their long-term exposure consequences. Many
therapeuticeﬀectsofcannabinoidsincludingmanagementof6 PPAR Research
glaucoma,rebelofinﬂammatoryandneuropathicpain,ame-
lioration of certain types of cancer, and various kinds of mo-
tordysfunctionassociatedwithmultiplesclerosis,spinalcord
injury, and ischemic stroke can be connected with PPARs as
well (Pertwee [45]). In summary, there is strong evidence to
suggest that some cannabinoids can act on PPARs through
either direct or indirect pathways. These discoveries not only
broaden the promising usage of cannabinoids as therapeu-
tic agents, but also support PPARs as new targets for some
neuroprotective treatment.
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